TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $47.11 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-05-06
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $47.11, a 4.97% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $43.01, a 66.58% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $43.45, a 28.89% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $44.88, a 27.90% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $45.78, a 28.60% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $35.60, a 129.83% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $15.49, a 15.68% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $18.37, a 51.73% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $47.11 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $45.78 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $43.01 10-Q · filed 2025-11-04 | $44.58 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $43.45 10-Q · filed 2025-08-06 | $44.76 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | $44.88 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $35.60 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $25.82 10-Q · filed 2025-11-04 | $34.66 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $33.71 10-Q · filed 2025-08-06 | $34.95 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $35.09 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $15.49 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $17.23 10-Q · filed 2024-11-13 | $15.43 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $15.55 10-Q · filed 2024-08-08 | $15.20 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $15.07 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $18.37 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $15.81 10-Q · filed 2023-11-09 | $18.43 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $14.85 10-Q · filed 2023-08-10 | $18.76 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $19.71 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $38.06 10-K · filed 2023-03-17 | |||
| 2020-12-31 | $4.16 10-K · filed 2022-03-14 | |||
| 2019-12-31 | $0.34 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |